Our next work would be to interrogate tumor gene expression datasets of NSCLC patients undergoing anti-PD-1 treatment to observe whether CD69 expression level correlates with clinical response rate, or resistance to therapy prior to or at different stages of treatment, and further explain the relevant mechanism. The gene discussed is CD69; the disease is non-small cell lung carcinoma.